Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors

PURPOSE: Etirinotecan pegol (EP), a long-acting topoisomerase-1 inhibitor, is a polyethylene glycol conjugate of irinotecan, with an intended indication for treatment of breast cancer with brain metastases. The objective of this study was to develop a population pharmacokinetic (popPK) model of EP a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sy, Sherwin K. B., Chia, Yen Lin, Gordi, Toufigh, Hoch, Ute, Eldon, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907632/
https://www.ncbi.nlm.nih.gov/pubmed/29564497
http://dx.doi.org/10.1007/s00280-018-3562-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907632/
https://www.ncbi.nlm.nih.gov/pubmed/29564497
http://dx.doi.org/10.1007/s00280-018-3562-3

Ejemplares similares